Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of setmelanotide in obesity with specific genetic variants
NL-OMON60809Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Oct 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Setmelanotide with Placebo (2 arms). Primary endpoint: Mean change in body weight/BMI-related measure at 52 weeks. Started Oct 2022; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON60809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60809.